Overview

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

Status:
RECRUITING
Trial end date:
2028-01-14
Target enrollment:
Participant gender:
Summary
This is a single-armed, single-centre, non-blinded phase II trial to assess efficacy of induction chemo-immunotherapy for resectable node-positive squamous cell carcinoma of the penis
Phase:
PHASE2
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborator:
Merck Sharp & Dohme LLC
Treatments:
CP protocol
pembrolizumab